Pharmaceutical

VistaGen Therapeutics received a notice from the US Patent and Trademark Office regarding the certain methods of production for AV-101.

VistaGen Therapeutics (NASDAQ:VTGN) received a notice from the US Patent and Trademark Office regarding the certain methods of production for AV-101.
As quoted in the press release:

“We are pleased that the USPTO has allowed this U.S. patent relating to production methods for AV-101 at this significant period in its clinical development. Together with other granted patents and pending patent applications, this new patent will enhance our exclusivity for AV-101,” stated Shawn Singh, Chief Executive Officer of VistaGen. “We are also pleased that a corresponding patent application has been granted in China. Together with the Notice of Intention to Grant European Patent 2948140B1, which relates to treatment of depression with AV-101 and its use to reduce levodopa-induced dyskinesia associated with Parkinson’s disease therapy, this Notice of Allowance in the U.S. is yet another important step forward, further strengthening and expanding our AV-101 IP portfolio.”

Click here to read the full press release.

Source: www.marketwired.com

Featured

MARKETS

Markets
TSX20181.92+80.54
TSXV705.58+14.41
DOW31253.13-236.94
S&P 5003900.79-22.89
NASD11388.50-29.66
ASX7064.50-118.20

COMMODITIES

Commodities
Gold1840.78-1.41
Silver21.87-0.03
Copper4.27-0.01
Palladium2016.82+12.81
Platinum963.00+4.00
Oil111.55-0.66
Heating Oil3.65-0.01
Natural Gas8.05-0.26

DOWNLOAD FREE REPORTS

×